Literature DB >> 15253490

Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide.

M Detry-Morel1, A Escarmelle, I Hermans.   

Abstract

PURPOSE: to report a case of severe ocular hypertension occurring as a complication after a single intravitreal injection of triamcinolone acetonide for the treatment of a diabetic cystoid macular edema.
METHODS: interventional case report.
RESULTS: a 63-year-old pseudophakic diabetic woman developed a severe and relatively sudden IOP increase to 50 mm Hg one month after receiving a single 4-mg intravitreal injection of triamcinolone acetonide for a chronic progressive macular cystoid edema. Previously the patient who did not develop corticosteroid-induced glaucoma secondary to her cataract surgery was treated with topical beta-blockers for a mild chronic bilateral ocular hypertension. A deep sclerectomy had to be performed in emergency to avoid optic nerve damage and allowed to successfully control the IOP with a 5 month follow-up. Concomitantly visual acuity could be increased from 0.05 before the intravitreal injection to 0.4.
CONCLUSIONS: Although unfrequent in the literature, this observation confirms the risk of occurrence of a severe ocular hypertension after intravitreal injection of triamcinolone. A close monitoring of IOP is mandatory after intravitreal injection, especially in patients with altered trabecular function. This potentially devastating complication has to be weighed up with the benefices of intravitreal injection of triamcinolone for improving visual acuity in patients with clinically significant diabetic macular edema.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253490

Source DB:  PubMed          Journal:  Bull Soc Belge Ophtalmol        ISSN: 0081-0746


  7 in total

1.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

2.  Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study.

Authors:  Oswaldo Ferreira Moura Brasil; Scott D Smith; Anat Galor; Careen Y Lowder; Jonathan E Sears; Peter K Kaiser
Journal:  Br J Ophthalmol       Date:  2006-11-15       Impact factor: 4.638

3.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.

Authors:  Hongkwan Cho; Siva P Kambhampati; Michael J Lai; Lingli Zhou; Grace Lee; Yangyiran Xie; Qiaoyan Hui; Rangaramanujam M Kannan; Elia J Duh
Journal:  Adv Ther (Weinh)       Date:  2020-11-09

5.  European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminologySupported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology.

Authors: 
Journal:  Br J Ophthalmol       Date:  2017-04-18       Impact factor: 4.638

6.  Canaloplasty in Corticosteroid-Induced Glaucoma. Preliminary Results.

Authors:  Paolo Brusini; Claudia Tosoni; Marco Zeppieri
Journal:  J Clin Med       Date:  2018-02-11       Impact factor: 4.241

Review 7.  Intravitreal steroids for the treatment of retinal diseases.

Authors:  Valentina Sarao; Daniele Veritti; Francesco Boscia; Paolo Lanzetta
Journal:  ScientificWorldJournal       Date:  2014-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.